Literature DB >> 32506181

Eosinophilic Esophagitis: Existing and Upcoming Therapies in an Age of Emerging Molecular and Personalized Medicine.

Ian F Slack1, Justin T Schwartz1, Vincent A Mukkada2, Shawna Hottinger1, J Pablo Abonia3.   

Abstract

PURPOSE OF REVIEW: Recent research efforts have spurred great progress in the diagnosis and management of eosinophilic esophagitis (EoE). Nonetheless, challenges remain in addressing disease burden and impairment in the growing EoE population. We highlight work from the Cincinnati Center for Eosinophilic Disorders, the Consortium of Eosinophilic Gastrointestinal Disease Researchers, and others that address these ongoing challenges. RECENT
FINDINGS: New tools for characterizing EoE disease activity include the EoE Histology Scoring System (EoEHSS), endoscopic alternatives, validated patient-reported outcome (PRO) questionnaires, and investigational biomarkers. These diagnostic and monitoring strategies have been complemented by advances in EoE therapy. Treatment modalities have refined the traditional approaches of dietary elimination, swallowed steroids, and proton pump inhibitors (PPI), and biologics offer promise for future treatment. This review summarizes EoE advances in disease management and newly defined EoE endotypes that may serve as the foundation for EoE-personalized medicine.

Entities:  

Keywords:  Diagnosis; Endotype; Eosinophilic esophagitis; Treatment

Mesh:

Year:  2020        PMID: 32506181      PMCID: PMC8034809          DOI: 10.1007/s11882-020-00928-2

Source DB:  PubMed          Journal:  Curr Allergy Asthma Rep        ISSN: 1529-7322            Impact factor:   4.806


  90 in total

1.  RPC4046, a Monoclonal Antibody Against IL13, Reduces Histologic and Endoscopic Activity in Patients With Eosinophilic Esophagitis.

Authors:  Ikuo Hirano; Margaret H Collins; Yehudith Assouline-Dayan; Larry Evans; Sandeep Gupta; Alain M Schoepfer; Alex Straumann; Ekaterina Safroneeva; Michael Grimm; Heather Smith; Cindy-Ann Tompkins; Amy Woo; Robert Peach; Paul Frohna; Sheila Gujrathi; Darryl N Penenberg; Caiyan Li; Gregory J Opiteck; Allan Olson; Richard Aranda; Marc E Rothenberg; Evan S Dellon
Journal:  Gastroenterology       Date:  2018-11-02       Impact factor: 22.682

2.  The Anti-α4β7 Integrin Therapeutic Antibody for Inflammatory Bowel Disease, Vedolizumab, Ameliorates Eosinophilic Esophagitis: a Novel Clinical Observation.

Authors:  Quan M Nhu; Hellen Chiao; Fouad J Moawad; Fei Bao; Gauree G Konijeti
Journal:  Am J Gastroenterol       Date:  2018-06-12       Impact factor: 10.864

3.  IL-13 induces esophageal remodeling and gene expression by an eosinophil-independent, IL-13R alpha 2-inhibited pathway.

Authors:  Li Zuo; Patricia C Fulkerson; Fred D Finkelman; Melissa Mingler; Christine A Fischetti; Carine Blanchard; Marc E Rothenberg
Journal:  J Immunol       Date:  2010-06-11       Impact factor: 5.422

4.  High prevalence of eosinophilic esophagitis in patients with inherited connective tissue disorders.

Authors:  J Pablo Abonia; Ting Wen; Emily M Stucke; Tommie Grotjan; Molly S Griffith; Katherine A Kemme; Margaret H Collins; Philip E Putnam; James P Franciosi; Karl F von Tiehl; Brad T Tinkle; Keith A Marsolo; Lisa J Martin; Stephanie M Ware; Marc E Rothenberg
Journal:  J Allergy Clin Immunol       Date:  2013-04-19       Impact factor: 10.793

5.  Development of the asthma control test: a survey for assessing asthma control.

Authors:  Robert A Nathan; Christine A Sorkness; Mark Kosinski; Michael Schatz; James T Li; Philip Marcus; John J Murray; Trudy B Pendergraft
Journal:  J Allergy Clin Immunol       Date:  2004-01       Impact factor: 10.793

Review 6.  Thoughts on the complex relationship between gastroesophageal reflux disease and eosinophilic esophagitis.

Authors:  Stuart Jon Spechler; Robert M Genta; Rhonda F Souza
Journal:  Am J Gastroenterol       Date:  2007-06       Impact factor: 10.864

7.  Development of a validated patient-reported symptom metric for pediatric eosinophilic esophagitis: qualitative methods.

Authors:  James P Franciosi; Kevin A Hommel; Charles W DeBrosse; Allison B Greenberg; Alexandria J Greenler; J Pablo Abonia; Marc E Rothenberg; James W Varni
Journal:  BMC Gastroenterol       Date:  2011-11-18       Impact factor: 3.067

8.  The oesophageal string test: a novel, minimally invasive method measures mucosal inflammation in eosinophilic oesophagitis.

Authors:  Glenn T Furuta; Amir F Kagalwalla; James J Lee; Preeth Alumkal; Brian T Maybruck; Sophie Fillon; Joanne C Masterson; Sergei Ochkur; Cheryl Protheroe; Wendy Moore; Zhaoxing Pan; Katie Amsden; Zachary Robinson; Kelley Capocelli; Vince Mukkada; Dan Atkins; David Fleischer; Lindsay Hosford; Mark A Kwatia; Shauna Schroeder; Caleb Kelly; Mark Lovell; Hector Melin-Aldana; Steven J Ackerman
Journal:  Gut       Date:  2012-08-15       Impact factor: 23.059

9.  Proton Pump Inhibitors and the Risk for Fracture at Specific Sites: Data Mining of the FDA Adverse Event Reporting System.

Authors:  Liwei Wang; Mei Li; Yuying Cao; Zhengqi Han; Xueju Wang; Elizabeth J Atkinson; Hongfang Liu; Shreyasee Amin
Journal:  Sci Rep       Date:  2017-07-17       Impact factor: 4.379

10.  Monitoring Eosinophilic Esophagitis Disease Activity With Blood Eosinophil Progenitor Levels.

Authors:  Anna Henderson; Adam Magier; Justin T Schwartz; Lisa J Martin; Margaret H Collins; Philip E Putnam; Vincent A Mukkada; J Pablo Abonia; Marc E Rothenberg; Patricia C Fulkerson
Journal:  J Pediatr Gastroenterol Nutr       Date:  2020-04       Impact factor: 3.288

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.